Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements examine found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://jeffh085cpv4.rimmablog.com/profile